|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||403.477 g/mol g·mol−1|
|3D model (JSmol)|
Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed. It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT1B (pKi = 9.4–10.1; IA = 94%) and 5-HT1D receptors (pKi = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs. Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.
(no additional rings)
(piperazine attached via side chain)
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|